Tryton Medical, Inc. (Tryton), a developer of stents designed to definitively treat bifurcation lesions, has been awarded US patent for Tryton Side Branch Stent System desigend for treating bifurcation lesions.

“We’re very pleased that a United States patent has been awarded to Tryton Medical for the unique Tryton Side Branch Stent System, which is treating some of the most challenging interventional cases in cardiovascular disease,” said J. Greg Davis, president and chief executive officer of Tryton Medical.

“This patent represents an important milestone for the company and our investors and is one of a family of patents currently under review at the Patent Office,” added chief technical officer H. Richard Davis.

The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. These areas of the vascular system are a common location for plaque and are particularly challenging to treat with currently available stent systems.

Tryton’s highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

The Tryton Side Branch Stent System demonstrated positive six-month clinical results in a first-in-man study of the system in 30 patients, with no restenosis occurring in the side branch artery. The stent system has received CE Mark approval in Europe and is not approved in the US.